The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis.
Standard
The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. / Schubert, Maria; Joniau, Steven; Gontero, Paolo; Kneitz, Susanne; Scholz, Claus-Jürgen; Kneitz, Burkhard; Briganti, Alberto; Karnes, R Jeffrey; Tombal, Bertrand; Walz, Jochen; Hsu, Chao-Yu; Marchioro, Giansilvio; Bader, Pia; Bangma, Chris; Frohneberg, Detlef; Graefen, Markus; Schröder, Fritz; van Cangh, Paul; van Poppel, Hein; Spahn, Martin.
In: ADV UROL, Vol. 2012, 2012, p. 612707.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis.
AU - Schubert, Maria
AU - Joniau, Steven
AU - Gontero, Paolo
AU - Kneitz, Susanne
AU - Scholz, Claus-Jürgen
AU - Kneitz, Burkhard
AU - Briganti, Alberto
AU - Karnes, R Jeffrey
AU - Tombal, Bertrand
AU - Walz, Jochen
AU - Hsu, Chao-Yu
AU - Marchioro, Giansilvio
AU - Bader, Pia
AU - Bangma, Chris
AU - Frohneberg, Detlef
AU - Graefen, Markus
AU - Schröder, Fritz
AU - van Cangh, Paul
AU - van Poppel, Hein
AU - Spahn, Martin
PY - 2012
Y1 - 2012
N2 - Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n = 86) or no adjuvant ADT (group 2, n = 86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5-10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.
AB - Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n = 86) or no adjuvant ADT (group 2, n = 86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5-10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.
U2 - 10.1155/2012/612707
DO - 10.1155/2012/612707
M3 - SCORING: Journal article
VL - 2012
SP - 612707
JO - ADV UROL
JF - ADV UROL
SN - 1687-6369
ER -
